Signal Transduction and Targeted Therapy (STTr) is a scholarly journal dedicated to publishing research in the field of Biochemistry Genetics and Molecular Biology. Springer is the publisher of this esteemed journal. The P-ISSN assigned to Signal Transduction and Targeted Therapy is 2095-9907 and its abbreviated form is Signal Transduct Target Ther.
Signal Transduction and Targeted Therapy is an international, peer-reviewed, open-access journal that publishes original research articles and review articles related to all aspects of signal transduction in physiological and pathological processes, as well as signal transduction-targeted therapeutics in the form of biological agents and small molecular drugs used to treat human diseases such as cancer, autoimmune disorders, and others. This journal focuses on cutting-edge advances both experimentally and clinically.
| Journal title | Signal Transduction and Targeted Therapy (STTr) |
| Abbreviation | Signal Transduct Target Ther |
| Print ISSN | 2095-9907 |
| Online ISSN | 2059-3635 |
| Publisher Name | Springer |
| Editor-in-chief | Prof. Carlo M. Croce, Institute of Genetics, The Ohio State University, Columbus, Ohio, USA |
| Subject Category | Biochemistry Genetics and Molecular Biology |
Signal Transduction and Targeted Therapy Abbreviation : ISO Journal abbreviation refers to the shortened form or acronym used to represent the full title of a scholarly journal. The ISO4 Abbreviation of Signal Transduction and Targeted Therapy Journal is Signal Transduct Target Ther.
The Ranking of Signal Transduction and Targeted Therapy in 2026 is 156. Ranking systems aim to provide an indication of a journal's quality, influence, and prestige within a specific field or discipline.
The Impact Factor of Signal Transduction and Targeted Therapy in 2026 is 37.2. it is all calculated by Clarivate, which means how many times a particular citation has been published in the past two years.
The SCImago of Signal Transduction and Targeted Therapy in 2026 is 6.630. It is measured by the number of citations which are made by the particular journals, and the journal from where the citations arrived from.
The H-Index of Signal Transduction and Targeted Therapy in 2026 is 83. The H-index is calculated on how many times a particular author is cited and the number of published papers that a particular author has.
The Quartile of Signal Transduction and Targeted Therapy is Q1. A quartile has three points, which are the upper quartile, median, and lower quartile. The main motive of the quartile is to calculate the interquartile range, that resembles the changes across the median.
The Signal Transduction and Targeted Therapy is indexed in (Indexing details)
| PubMed | Scopus | Web of Science | UGC | Embase | DOAJ |
|---|---|---|---|---|---|
| ✅ | ✅ | ❌ | ✅ | ✅ | ❌ |
Indexing services aim to make it easier for researchers, scholars, and readers to discover and access articles from various journals within a specific field or discipline.
| Abbreviation | Signal Transduct Target Ther |
| Access type | Open Access |
| Impact Factor | 37.2 |
| SJR | 6.630 |
| SNIP | 4.133 |
| Ranking | 156 |
| CiteScore | 31.5 |
| H-Index | 83 |
The Editor-in-chief of Signal Transduction and Targeted Therapy is Prof. Carlo M. Croce, Institute of Genetics, The Ohio State University, Columbus, Ohio, USA
Signal Transduction and Targeted Therapy Processing/Submission Fee : Article submission/Processing fees (APC), also known as manuscript Publication fees or processing fees (APC), are charged by journals to authors for submitting/publishing their research papers/article.
The APC/Submission (Publication) Fee of Signal Transduction and Targeted Therapy is $3190, £2390, €2690
Signal Transduction and Targeted Therapy Call for paper : Signal Transduction and Targeted Therapy invites original research contributions for consideration of publication in Signal Transduction and Targeted Therapy journal.
Journal seeking submissions in the broad areas of Biochemistry Genetics and Molecular Biology that align with journal's focus on Biochemistry Genetics and Molecular Biology.
for details about call for paper please visit to the official website of the journal to check the details about call for papers.
Publishing in Signal Transduction and Targeted Therapy involves the following steps:
Yes, the Signal Transduction and Targeted Therapy journal is indexed in PubMed.
Yes, the Signal Transduction and Targeted Therapy journal is indexed in Scopus.
Yes, the Signal Transduction and Targeted Therapy journal is indexed in UGC.
No, the Signal Transduction and Targeted Therapy journal is not indexed in Index copernicus.
No, Signal Transduction and Targeted Therapy journal is not a predatory journal.
The Impact Factor of the Signal Transduction and Targeted Therapy is 37.2.
The Ranking of the Signal Transduction and Targeted Therapy is 156.
Yes the Signal Transduction and Targeted Therapy (STTr) journal is a peer-reviewed journal.
Yes the Signal Transduction and Targeted Therapy journal is a peer-reviewed journal and good to publish your paper.
Signal Transduction and Targeted Therapy (STTr) is a scholarly journal dedicated to publishing research in the field of Biochemistry Genetics and Molecular Biology. Springer is the publisher of this esteemed journal.
Yes, Signal Transduction and Targeted Therapy is a open access journal.